4.7 Editorial Material

TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?

Journal

CLINICAL CANCER RESEARCH
Volume 26, Issue 9, Pages 2085-2086

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-20-0387

Keywords

-

Categories

Ask authors/readers for more resources

The impact on survival of steroids and TNF alpha blockade to treat immune-related toxicity from checkpoint blockade with ipilimumab, nivolumab/pembrolizumab, or combined ipilimumab and nivolumab was assessed using data from a large national database. Using steroids was associated with better survival than the use of TNF alpha-blocking antibodies such as infliximab.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available